HC Wainwright Has Negative View of Humacyte FY2024 Earnings

Humacyte, Inc. (NASDAQ:HUMA) – Equities research analysts at HC Wainwright lowered their FY2024 EPS estimates for Humacyte in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst V. Bernardino now forecasts that the company will post earnings per share of ($1.36) for the year, down from their previous forecast of ($1.28). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.18) per share. HC Wainwright also issued estimates for Humacyte’s FY2025 earnings at ($0.77) EPS.

A number of other research analysts have also recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price objective on shares of Humacyte in a research note on Friday, September 20th. Benchmark reissued a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a research note on Thursday, October 10th. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. BTIG Research reissued a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. Finally, Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $11.00.

Humacyte Stock Performance

Shares of NASDAQ:HUMA opened at $4.84 on Friday. The company’s 50 day simple moving average is $5.44 and its 200 day simple moving average is $6.17. The stock has a market capitalization of $577.65 million, a price-to-earnings ratio of -3.66 and a beta of 1.47. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 5.41. Humacyte has a 1 year low of $2.35 and a 1 year high of $9.97.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04).

Insider Activity at Humacyte

In other news, CFO Dale A. Sander sold 39,389 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $6.68, for a total transaction of $263,118.52. Following the transaction, the chief financial officer now owns 2,000 shares in the company, valued at approximately $13,360. This represents a 95.17 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Brady W. Dougan sold 252,676 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the transaction, the director now owns 4,306,464 shares in the company, valued at $28,896,373.44. This represents a 5.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,084,153 shares of company stock worth $6,869,996 over the last quarter. Company insiders own 11.20% of the company’s stock.

Institutional Investors Weigh In On Humacyte

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Endowment Wealth Management Inc. raised its holdings in shares of Humacyte by 3.1% in the 2nd quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company’s stock worth $482,000 after acquiring an additional 3,000 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of Humacyte in the 2nd quarter worth about $28,000. Private Advisor Group LLC grew its position in Humacyte by 1.8% in the 3rd quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock worth $2,030,000 after purchasing an additional 6,510 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Humacyte by 32.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock worth $168,000 after purchasing an additional 8,557 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in Humacyte by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock worth $125,000 after purchasing an additional 8,965 shares in the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.